Document:

Exhibit 4.31
​
EXCLUSIVE LICENSE AGREEMENT RENEWAL
THIS RENEWAL OF THE EXCLUSIVE LICENSE AGREMEMENT (this “Renewal”) is made and entered into as of May 8, 2020, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
RECITALS
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT dated October 17, 2019;
WHEREAS, the Parties hereby agree to renew and extend the EXCLUSIVE LICENSE AGREEMENT as follows:
	1.
	Section 7.0 License Fee.  As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars (USD $1,000,000) (“License Fee”).  In the event that the Licensee’s initial funding event is equal to or greater than ten million USD (USD $10,000,000), the full License Fee shall be payable immediately upon the successful closing of the initial funding event.  In the event that any funding event is less than USD$ 10,000,000, Licensee will pay Skinvisible a non-refundable 10% of the net amount raised in any funding event until the full License Fee is paid, due no later than July 31, 2020.  This Agreement will automatically terminate if the License Fee is not paid by July 31, 2020.  Licensee agrees to hold bi-monthly update calls with Skinvisible on the status of funding until such time the full License Fee is paid.

	2.
	All other terms and conditions of the Exclusive License Agreement shall remain unchanged.

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first above written.
	​

	​

	​

	​

	SKINVISIBLE, INC.

	​

	​

	​

	By:  

	/s/ Terry Howlett

	​

	Name:  

	Terry Howlett

	​

	Title:  

	President & Chief Executive Officer

​
	​

	​

	​

	​

	QUOIN PHARMACEUTICALS, INC.

	​

	​

	​

	By:  

	/s/ Michael Myers

	​

	Name:  

	Michael Myers, Ph.D.

	​

	Title:  

	President & Chief Executive Officer

​​

Exhibit 4.32
​
​
FIRST AMENDMENT TO THE
EXCLUSIVE LICENSE AGREEMENT
by and among
SKINVISIBLE, INC.,
QUOIN PHARMACEUTICALS, INC.,
Dated as of October 17, 2019
​
​

​

​

FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT (this “Amendment”) is made and entered into as of July 31, 2020, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
RECITALS
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT dated October 17, 2019;
WHEREAS, the Parties hereby amend the EXCLUSIVE LICENSE AGREEMENT as follows:
	1.
	Section 7.0 License Fee.  As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars (USD $1,000,000) (“License Fee”).  In the event that the Licensee’s initial funding event is equal to or greater than ten million USD (USD $10,000,000), the full License Fee shall be payable immediately upon the successful closing of the initial funding event.  In the event that any funding event is less than USD$ 10,000,000, Licensee will pay Skinvisible a non-refundable 10% of the net amount raised in any funding event until the full License Fee is paid, due no later than September 30, 2020.  This Agreement will automatically terminate if the License Fee is not paid by September 30, 2020.  Licensee agrees to hold bi-monthly update calls with Skinvisible on the status of funding until such time the full License Fee is paid.

	2.
	All other terms and conditions of the Exclusive License Agreement shall remain unchanged.

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first above written.
	​

	​

	​

	​

	SKINVISIBLE, INC.

	​

	​

	​

	By:  

	/s/ Terry Howlett

	​

	Name:  

	Terry Howlett

	​

	Title:  

	President & Chief Executive Officer

​
	​

	​

	​

	​

	QUOIN PHARMACEUTICALS, INC.

	​

	​

	​

	By:  

	/s/ Michael Myers

	​

	Name:  

	Michael Myers, Ph.D.

	​

	Title:  

	President & Chief Executive Officer

​

​Exhibit 4.33
​
​
SECOND AMENDMENT TO THE
EXCLUSIVE LICENSE AGREEMENT RENEWAL
by and among
SKINVISIBLE, INC.,
QUOIN PHARMACEUTICALS, INC.,
Dated as of May 8, 2020
​
​
​

SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL
​
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT RENEWAL  (this “Amendment”) is made and entered into as of September 30, 2020, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
​
RECITALS
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT dated October 17, 2019;
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT RENEWAL dated May 8, 2020;
WHEREAS, the Parties have entered into the FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL dated July 31, 2020;
WHEREAS, the Parties hereby amend the EXCLUSIVE LICENSE AGREEMENT RENEWAL  as follows:
​
		1.
	Section 7.0 License Fee. As partial consideration for the rights conveyed by Skinvisible under this Agreement, Licensee agrees to pay to Skinvisible a one-time, non-refundable, non-creditable license issue fee of one million USD dollars (USD $1,000,000) (“License Fee”) payable as follows:

		1.1
	The Licensee is currently raising Initial Bridge Financing targeted to be a total of $3,000,000. Upon receipt of the Initial Bridge Financing, Licensee shall pay Skinvisible 10% of the total amount of Initial Bridge Financing.

		1.2
	The Licensee has agreed terms with Altium Capital for a Second Bridge Financing totaling $3.750,000 across three tranches. The Second Bridge Financing will be paid to the Licensee upon the signing of a definitive merger agreement with a publicly listed company. Upon receipt of each tranche of the Second Bridge Financing, Licensee shall pay Skinvisible 10% of each tranche of the Second Bridge Financing.

		1.3
	The Licensee has a greed terms with Altium Capital for an Investment in the company totaling $21,500,000-30,000,000.  This Investment will be paid to the Licensee upon the successful closing of a reverse merger with a publicly listed company. Upon receipt of the Investment, Licensee shall pay Skinvisible the remaining outstanding balance of the License Fee.

		2.
	All other terms and conditions of the Exclusive License Agreement shall remain unchanged.

​

​
IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first above written.
​
	​

	​

	​

	​

	SKINVISIBLE, INC.

	​

	​

	​

	By:  

	/s/ Terry Howlet

	​

	Name:  

	Terry Howlett

	​

	Title:  

	President & Chief Executive Officer

​
	​

	​

	​

	​

	QUOIN PHARMACEUTICALS, INC.

	​

	​

	​

	By:  

	/s/ Michael Myers

	​

	Name:  

	Michael Myers, Ph.D.

	​

	Title:  

	President & Chief Executive Officer

​Exhibit 4.34
	​
​
​
​
​
​

	THIRD AMENDMENT TO THE
EXCLUSIVE LICENSE AGREEMENT RENEWAL
by and among
SKINVISIBLE, INC.,
QUOIN PHARMACEUTICALS, INC.,
Dated as of January 27, 2021

​
​

THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT RENEWAL (this “Amendment”) is made and entered into as of January 27, 2021, by and among Skinvisible, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
RECITALS
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT dated October 17, 2019;
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT RENEWAL dated May 8, 2020;
WHEREAS, the Parties have entered into the FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL dated July 31, 2020;
WHEREAS, the Parties have entered into the SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL dated September 30, 2020;
WHEREAS, the Parties hereby amend the EXCLUSIVE LICENSE AGREEMENT RENEWAL as follows:
		1.
	Section 7.3.1 Clinical Milestones and Milestone Payments:

		(i)	Successful completion of Phase 2 testing:  $250,000

		(ii)	Successful completion of Phase 3 testing:  $500,000

		(iii)	Regulatory approval in US: $14,500,000

		(iv)	Regulatory approval in EU: $7,250,000

		2.
	All other terms and conditions of the Exclusive License Agreement Renewal and Amendments shall remain unchanged.

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first above written.
​
	​
	​
	SKINVISIBLE, INC.

	​
	​

	​
	By:
	/s/ Terry Howlett

	​
	Name:
	Terry Howlett

	​
	Title:
	President & Chief Executive Officer

	​
	​
	​

	​
	​
	QUOIN PHARMACEUTICALS, INC.

	​
	​
	​

	​
	By:
	/s/ Michael Myers

	​
	Name:
	Michael Myers, Ph.D.

	`
	Title:
	President & Chief Executive Officer

	​
	​

​Exhibit 4.35
	​
​
​
​
​
​

	FOURTH AMENDMENT TO THE
EXCLUSIVE LICENSE AGREEMENT and RENEWAL
by and among
SKINVISIBLE PHARMACEUTICALS, INC.,
QUOIN PHARMACEUTICALS, INC.,
Dated as of April 19, 2021

​
​

FOURTH AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL
THIS AMENDMENT TO THE EXCLUSIVE LICENSE AGREMEMENT RENEWAL (this “Amendment”) is made and entered into as of April 19, 2021, by and among Skinvisible Pharmaceuticals, Inc., a Nevada corporation (referred to as “SKINVISIBLE” ), and Quoin Pharmaceuticals, Inc., a Delaware corporation (“Licensee”).
RECITALS
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT dated October 17, 2019;
WHEREAS, the Parties have entered into the EXCLUSIVE LICENSE AGREEMENT RENEWAL dated May 8, 2020;
WHEREAS, the Parties have entered into the FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL dated July 31, 2020;
WHEREAS, the Parties have entered into the SECOND AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL dated September 30, 2020;
WHEREAS, the Parties have entered into the THIRD AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT RENEWAL date January 27, 2021;
WHEREAS, the Parties hereby amend the EXCLUSIVE LICENSE AGREEMENT RENEWAL as follows:
		1.
	Section 7.5 Minimum Timeline of First Licensed Product: Licensee agrees to commence clinical testing on at least one Licensed Product in the Field by December 31, 2022 (“Development Deadline”) where clinical testing is defined as a study in which one or more human subjects are prospectively assigned to one or more interventions including a Licensed Product to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes In the event that Licensee has not commenced such testing by the Development Deadline, this Agreement will terminate immediately unless initiation of such testing has been materially delayed  due to the inability of Skinvisible to provide GMP grade polymer or as a result of  a delay by the FDA or another regulatory authority by putting the product on a clinical hold which would then put the Development Deadline on hold. Licensee will promptly inform Skinvisible if it receives a clinical hold from the FDA or another regulatory authority and Licensee will respond to the request in a timely fashion. . In the event Licensee concludes that successful resolution of the clinical hold is not feasible then Licensee will promptly inform Skinvisible that it is ceasing further development of that Licensed Product and Skinvisible will have the right to use or license its technology for that particular indication including the same active ingredient. Skinvisible, however, will not use any of  the use of Licensees confidential information. When the clinical hold has been fully lifted, the clock on the 12 month commitment will resume for an additional 12 month period.

		2.
	All other terms and conditions of the Exclusive License Agreement, Renewal and Amendments shall remain unchanged.

​

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed as of the date first above written.
	​
	SKINVISIBLE PHARMACEUTICALS, INC.

	​
	​

	​
	By:
	/s/ Terry Howlett

	​
	Name:
	Terry Howlett

	​
	Title:
	President & Chief Executive Officer

	​
	​

	​
	​

	​
	QUOIN PHARMACEUTICALS, INC.

	​
	​

	​
	By: 
	/s/ Michael Myers

	​
	Name: 
	Michael Myers, Ph.D.

	​
	Title: 
	President & Chief Executive Officer

	​
	​

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00343-of-00352.parquet"}]]